NCT07145047
Clinical Study of Oncolytic Virus in Glioblastoma
Recruiting · Phase 1, Phase 2 · Mianyang Central Hospital · registry updated 2025-12-19
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This clinical trial aims to evaluate whether an oncolytic viral agent can treat recurrent glioblastoma. It will also assess the safety and tolerability of the oncolytic viral agent. The primary question it seeks to answer is: What medical problems do participants experience when injected with the oncolytic viral agent? Researchers will administer the oncolytic viral agent via intratumoral injection to determine its efficacy in treating recurrent glioblastoma. Participant Procedures: Receive the initial injection, followed by additional injections every 2-4 weeks for a total of 6 injections. Undergo physical examinations and tests every 2 to 4 weeks. Record their symptoms, hematological test results, and imaging findings.
Inclusion
- Patients with recurrent glioblastoma, for whom the standard methods of treatment are considered ineffective by the medical commission.
- Histologically confirmed recurrent glioblastoma.
- Magnetic resonance imaging (MRI) showed that the maximum diameter of recurrent lesions is greater than 1.0 cm.
- Before inclusion of patients in the study, at least one of the following types of therapy was previously performed: 4.1 Time from the last radiotherapy/surgery is more than 28 days; 4.2 Subjects maintained stable or declining for at least 7 days prior to corticosteroid regimen; 4.3 Most recent antitumor therapy must have been completed within the specified time prior to treatment: vincristine 2 weeks, nitrosoureas 4 weeks, bevacizumab 4 weeks, temozolomide 6 weeks.
- Age \>=18 years, \<=70 years.
- Hematological indicators, kidney and liver function are normal.
Exclusion
- Incompatibility of patients with the inclusion criteria mentioned above.
- Participated in other drug clinical trials within 4 weeks
- Preoperative bleeding susceptibility or use of anticoagulants or any medication that may increase the risk of bleeding.
- Patients with extracranial metastases.
- Have poorly controlled clinical diseases, such as liver aminotransferase (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) or total bilirubin \> 2 times the upper normal limit.
- Female subjects: during pregnancy or lactation.